Adjuvant Systems

A unique portfolio for vaccine development

TLR-4 Agonists

Vaccine adjuvants using heterogeneous monophosphoryl Lipid A (MPL) derived from Salmonella minnesota R595 have proven to be safe and effective at inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines. Avanti revolutionized immunotherapy and vaccine development with the introduction of Synthetic MPL derivatives and adjuvant systems. Avanti now manufactures multiple synthetic analogs of MPL containing a single molecular species that are as effective and safe at inducing an immune response as their natural product predecessor.

PHAD™, 3D-PHAD™, and 3D-(6-acyl)-PHAD™ are manufactured according to cGMP guidelines and are available in bulk quantities for your clinical trials.

Licensing opportunities are available for your field of use. Please contact us at GMP@avantilipids.com for more information.

Mineral Adjuvants

Alum is the gold standard for safe and effective vaccine adjuvants. Alum acts as an "amplifier" for the innate immune response and enables a boost in antibody production. Alum can be combined with other adjuvants (such as synthetic monophosphory lipid A) to achieve a balanced Th1/Th2 immune response.

Alum has been used safely and effectively for more than 80 years in commercial vaccines.

Croda Pharma's Alhydrogel™ and Adju-Phos™ are widely recognized, market-leading adjuvants and are produced in the only aseptic manufacturing site for aluminum-based adjuvants, globally.

Saponins

QS-21

QS-21, a fraction from Quillaja saponaria Molina, is a fundamental building block in Th1 based adjuvant systems. QS-21 can induce a strong cell-mediated response against intracellular infections and is a potential activator of CD8+ T-cells). QS-21 should be formulated with a sterol or lipid to alleviate any safety issues (i.e. PHADs or cholesterol).

QS-21 was approved by the FDA in October 2017 in a vaccine against herpes zoster and post-herpetic neuralgia. A malaria vaccine containing QS-21 is also endorsed by the World Health Organization.

NanoQuil™

NanoQuil™ is Croda Pharma's proprietary third generation immunostimulating complex (ISCOM) adjuvant system, exerting a balanced Th1/Th2 immune response. This adjuvant system elicits a unique immunological response and a low reactogenicity profile. NanoQuil™ can increase the stability of saponins while incorporated in cholesterol.